Evogene Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Evogene de 37.4% y 45%, respectivamente.

Información clave

37.4%

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	49.5%
Tasa de crecimiento de los ingresos	45.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	22 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

TASE:EVGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	29	-16	N/A	N/A	2
12/31/2025	17	-20	N/A	N/A	2
12/31/2024	10	-22	N/A	N/A	1
9/30/2024	7	-24	-21	-20	N/A
6/30/2024	9	-20	-20	-20	N/A
3/31/2024	9	-21	-20	-19	N/A
12/31/2023	6	-24	-22	-22	N/A
9/30/2023	6	-20	-19	-18	N/A
6/30/2023	2	-23	-22	-21	N/A
3/31/2023	2	-25	-23	-22	N/A
12/31/2022	2	-27	-25	-24	N/A
9/30/2022	1	-31	-31	-30	N/A
6/30/2022	1	-32	-29	-28	N/A
3/31/2022	1	-29	-29	-28	N/A
12/31/2021	1	-28	-26	-25	N/A
9/30/2021	1	-29	-24	-24	N/A
6/30/2021	1	-26	-23	-22	N/A
3/31/2021	1	-24	-19	-19	N/A
12/31/2020	1	-23	-20	-20	N/A
9/30/2020	1	-21	-18	-17	N/A
6/30/2020	1	-21	-18	-17	N/A
3/31/2020	0	-21	-19	-18	N/A
12/31/2019	1	-18	-19	-18	N/A
9/30/2019	1	-18	-16	-16	N/A
6/30/2019	2	-18	-16	-16	N/A
3/31/2019	2	-19	-16	-16	N/A
12/31/2018	2	-21	-16	-15	N/A
9/30/2018	2	-21	-16	-16	N/A
6/30/2018	2	-21	N/A	-15	N/A
3/31/2018	3	-21	N/A	-16	N/A
12/31/2017	3	-21	N/A	-16	N/A
9/30/2017	4	-21	N/A	-17	N/A
6/30/2017	5	-21	N/A	-16	N/A
3/31/2017	5	-21	N/A	-15	N/A
12/31/2016	7	-20	N/A	-12	N/A
9/30/2016	8	-18	N/A	-12	N/A
6/30/2016	9	-17	N/A	-11	N/A
3/31/2016	10	-17	N/A	-12	N/A
12/31/2015	11	-17	N/A	-12	N/A
9/30/2015	12	-17	N/A	-10	N/A
6/30/2015	12	-17	N/A	-9	N/A
3/31/2015	13	-16	N/A	-8	N/A
12/31/2014	15	-15	N/A	-9	N/A
9/30/2014	17	-14	N/A	-8	N/A
6/30/2014	18	-12	N/A	-7	N/A
3/31/2014	18	-11	N/A	-6	N/A
12/31/2013	15	-9	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que EVGN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (45% al año) de EVGN crezcan más rápidamente que los del mercado IL (2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (45% al año) de EVGN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de EVGN se prevé que sea elevada dentro de 3 años.

Evogene Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022)

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022)

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022)

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021)

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021)

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021)

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day high: ₪25.00

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

New 90-day high: ₪19.10

New 90-day high: ₪14.94

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

First half earnings released

New 90-day high - ₪9.46

New 90-day high - ₪5.63

New 90-day high - ₪4.17

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento